Deals
BlueMountain Capital Management has entered into a consulting agreement with Harvard economics professor Jeremy C Stein, who was a member of the Board of Governors of the Federal Reserve System from May 2012 to May 2014.
Professor Stein will advise BlueMountain on a range of issues, including implications of monetary and macroprudential policies, financial regulation and market evolution, and risk and capital management.
"We're very lucky to have the opportunity to work with Jeremy," says Andrew Feldstein, CEO of BlueMountain. "He has been widely recognised by leaders in government, academia and the private sector for his talent and impact.
Victory Park Capital Advisors (Victory Park Capital) has been retained by newly formed, UK investment company VPC Speciality Lending (VPC) to serve as investment manager.
VPC completed its initial public offering of ordinary shares on the Main Market of the London Stock Exchange on 13 March.
As investment manager, Victory Park Capital will be charged with investing approximately USD300 million in opportunities within the specialty lending market primarily through online lending platforms.
“The significant growth in the specialty lending market through consumer and small business and direct lending electronic platforms and the success of the listing is a
P Schoenfeld Asset Management (PSAM) has submitted two resolutions on behalf of select clients who own 7,500,000 shares of Vivendi , to the company’s Management Board for inclusion on the agenda of the Company's Combined General Meeting to be held on 17 April, 2015.
PSAM's clients also own 3,189,281 additional shares of Vivendi. In aggregate, the shares have a market valuation of approximately EUR236,821,000 as of market-close on Friday, 20 March, 2015. PSAM has been a Vivendi shareholder since July 2012.
PSAM believes that Vivendi is significantly undervalued due to its excessive cash holdings, inadequate capital return policy and
Barbour ABI has been granted a contract extension by HM Government to continue to publish the Government Construction and National Infrastructure Pipelines through until August 2016.
Barbour ABI was originally awarded the contract in September 2012, following a formal competitive tender process, because of their proven data collection processes and their existing knowledge in researching and tracking construction projects.
Since 2011, the published Pipelines have expanded to include more data on projects and programmes across departments. The commitment to making the data more user friendly using mapping and timeline technology – as well as promoting the pipeline more widely across
An affiliate of private equity firm Warburg Pincus is to recapitalise Sterigenics, provider of contract sterilization, gamma technologies and medical isotopes, in partnership with private equity firm GTCR.
Terms of the transaction have not been disclosed. GTCR purchased Sterigenics in 2011.
“With this new partnership between Warburg Pincus and GTCR, Sterigenics is extraordinarily well positioned to accelerate growth, invest additional capital to serve our customers and expand our global footprint,” says Michael Mulhern, CEO of Sterigenics International.
Sterigenics’ growth over the past several years has reinforced its global market-leading position in the contract sterilization services industry. In 2014, Sterigenics acquired
Lending Works, the first peer-to-peer lender to have insurance against borrower default risk, is introducing several new features aimed at the UK pensions market, as new pension rule changes come into effect in April 2015.
More than 52% of Lending Works’ lenders are aged 55 or older, indicating a growing inclination among later-life lenders to make peer-to-peer lending a common feature of their retirement finance plans.
From early April 2015, Lending Works will offer four brand new features that make peer-to-peer lending even more appealing to pensioners who take control of their pensions and look for simple, personal, high-interest
JPMorgan Chase has awarded a USD1 million grant to VEDC to boost the organisation’s infrastructure as they expand their outreach to small businesses in eight states.
JPMorgan Chase has been a longtime supporter of VEDC as they strive to meet the capital needs of small businesses in underserved communities.
The USD1 million grant will help VEDC as they expand their small business loan programs across eight states to bring small business owners the access to capital so desperately needed to create new jobs. In addition, VEDC has expanded lending in Bakersfield, and is in the process of completing two studies
Remitly has closed a USD12.5 million Series B funding round led by DFJ with participation from DN Capital and existing investors QED Investors and Trilogy Equity Partners.
DFJ partner William Bryant will join Remitly’s board of directors. Remitly will use the new capital to expand its team, scale marketing efforts, and broaden the service to include new countries.
While the global economy becomes more integrated through technology, international money transfers remain antiquated. There are more than 200 million people who live abroad and send money home. These customers use remittance services that are often riddled with high and hidden fees,
Trax Technologies has completed its previously disclosed majority investment in Trax, made in partnership with Trax’s current management team, led by Founder and CEO J Scott Nelson.
The terms of the transaction have not been disclosed.
“With this transaction complete, we are excited to continue building the Trax platform and services in support of our current and future global customer base,” says Nelson. “This investment will support further development, deployment, and support of existing and new products and services benefiting both buyers and sellers of logistics services.”
Healthcare investment firm Vivo Capital has held the final closing of Vivo Capital Fund VIII at USD750 million, which brings the firm's total funds under management to more than USD1.7 billion.
Vivo plans to invest the capital primarily in later development stage pharmaceutical and medical device companies in the US and in revenue stage healthcare companies in greater China. Vivo plans to continue assisting companies in both countries in their efforts to forge cross-border partnerships, enabling companies to acquire new products and expand the market for their existing products. Vivo also intends to continue its successful strategies of building companies
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm